Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate CancerInterventions: Biological: Pembrolizumab; Biological: pTVG-HP Plasmid DNA VaccineSponsors: University of Wisconsin, Madison; National Cancer Institute (NCI)Not yet recruiting - verified July 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Hormone Resistant Prostate Cancer | Hormones | Prostate Cancer | Research | Vaccines